How Biden plans to change the US pandemic response

‘President-elect Joe Biden and Vice President-elect Kamala Harris say they will move the US Covid-19 pandemic response in a dramatically different direction... Here are five ways Biden says the US coronavirus response will change when he's President. (1) Increased testing and contact tracing. (2) Additional investment in vaccines and treatments. (3) Mandatory masks and more PPE. (4) A push for 'clear, consistent, evidence-based guidance'. (5) Rejoining WHO and searching for future threats.

‘There were dauntingly high new case numbers last week, and by the time Biden takes office January 20, the influential University of Washington Institute of Health Metrics and Evaluation model projects there will be more than 372,000 Covid-19 deaths -- that's 135,000 more than the current total...’

Read here (CNN, Nov 9, 2020)

Infectious Diseases Society of America (IDSA) issues guidelines on the treatment and management of patients with COVID-19

The IDSA have issued 7 recommendations on the treatment and management of COVID-19 patients. These are part of their aim to “develop evidence-based rapid guidelines intended to support patients, clinicians and other health-care professionals in their decisions about treatment and management of [these] patients.”

They recognise the limitations imposed by “the understandable urgency in producing, synthesising and disseminating data during the current pandemic”. In the rush to publish, there has been (1) circumvention of usual research steps (2) limited peer-review process and (3) increased potential for publication bias (in the interest of showing promising data and in the race to achieve recognition).

The recommendations are based on “evidence from the best available clinical studies with patient-important endpoints”. They also discuss trade-offs between “highly uncertain benefits” and “known putative harms”. They cover treatments involving drugs like azithromycin, hydroxychloroquine, lopinavir-ritonavir, corticosteroids and tocilizumab.

Read here (IDSA, March 11, 2020)